Bookbot

Ernst Schering Research Foundation Workshop - 40: Recent Advances in Glucocorticoid Receptor Action

Más información sobre el libro

The long-term use of glucocorticoids is associated with several deleterious effects. Attempts to separate the beneficial from the adverse effects of these compounds have met with varying degrees of difficulty. The discovery of distinct modes of action of the glucocorticoid receptor, the protein that mediates glucocorticoid action has opened up many possibilities for improving glucocorticoid therapy. This book provides an in-depth overview of the molecular actions of the glucocorticoid receptor and discusses the chances of an imminent identification of selective glucocorticoid agonists. Such componds should fulfill all the criteria of a glucocorticoid but should lack the sideeffects so far linked with classical glucocorticoids.

Compra de libros

Ernst Schering Research Foundation Workshop - 40: Recent Advances in Glucocorticoid Receptor Action, A.C.B. Cato, H. Schacke, K. Asadullah

Idioma
Publicado en
2002
product-detail.submit-box.info.binding
(Tapa dura)
Te avisaremos por correo electrónico en cuanto lo localicemos.

Métodos de pago

Nadie lo ha calificado todavía.Añadir reseña

Título
Ernst Schering Research Foundation Workshop - 40: Recent Advances in Glucocorticoid Receptor Action
Idioma
Inglés
Editorial
Springer
Publicado en
2002
Formato
Tapa dura
Páginas
384
ISBN10
3540432299
ISBN13
9783540432296
Serie
Descripción
The long-term use of glucocorticoids is associated with several deleterious effects. Attempts to separate the beneficial from the adverse effects of these compounds have met with varying degrees of difficulty. The discovery of distinct modes of action of the glucocorticoid receptor, the protein that mediates glucocorticoid action has opened up many possibilities for improving glucocorticoid therapy. This book provides an in-depth overview of the molecular actions of the glucocorticoid receptor and discusses the chances of an imminent identification of selective glucocorticoid agonists. Such componds should fulfill all the criteria of a glucocorticoid but should lack the sideeffects so far linked with classical glucocorticoids.